Back to search

Article

Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in <i>FLT3</i> , <i>TP53,</i> and <i>MUC4</i> mutations

2024-12-31

Abstract excerpt

Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy characterized by the clonal expansion of myeloid precursor cells. Advances in genomic profiling have enhanced our understanding of AML pathogenesis, leading to the identification of recurrent mutations, including TP53, FLT3, MUC4, RAS, and IDH1/2 . These mutations significantly influence treatment response and prognosis, with TP53 mutations...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f2d91e63-81e0-5a38-ad28-0c59fbbe42ac
DOI
10.1101/2024.12.31.630711
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in <i>FLT3</i> , <i>TP53,</i> and <i>MUC4</i> mutationsDOI 10.1101/2024.12.31.630711
Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in <i>FLT3-</i> and <i>KIT-</i> Mutant AMLSemantic proximity
Anlotinib Induced Venetoclax-resistant Acute Myeloid Leukemia Stem Cells Apoptosis through Downregulating Mcl-1-mediated Anti-apoptoeic PathwaySemantic proximity
Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatmentsSemantic proximity
Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.Semantic proximity
An in vivo CRISPR screening platform for prioritizing therapeutic targets in AMLSemantic proximity
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Semantic proximity
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaSemantic proximity
Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML CellsSemantic proximity
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.Semantic proximity
P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.Semantic proximity
Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity
Select a neighboring publication to make it the new centre.